(Q44261951)

English

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study (English)

1 reference

Europe PubMed Central

1 December 2017

1 reference

based on heuristic

inferred from title

author name string

James A Simon

1

1 reference

Europe PubMed Central

1 December 2017

E Michael Lewiecki

2

1 reference

Europe PubMed Central

1 December 2017

Mary E Smith

3

1 reference

Europe PubMed Central

1 December 2017

Richard A Petruschke

4

1 reference

Europe PubMed Central

1 December 2017

Lixia Wang

5

1 reference

Europe PubMed Central

1 December 2017

Joanne J Palmisano

6

1 reference

Europe PubMed Central

1 December 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

1 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

1 December 2017

24

1 reference

Europe PubMed Central

1 December 2017

11

1 reference

Europe PubMed Central

1 December 2017

1871-1886

1 reference

Europe PubMed Central

1 December 2017

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Reasons for adherence with antihypertensive medication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to pharmacologic management of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly administration of alendronate: rationale and plan for clinical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Note on the sampling error of the difference between correlated proportions or percentages

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues in patient compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Some relevant components of adherence behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for enhancing patient compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Polypharmacy: the cure becomes the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980085-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(02)80085-6

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44261951&oldid=2108974634"